Novartis’ Sandoz last week launched the...

...first generic for United Therapeutics’ Remodulin, a pulmonary arterial hypertension drug. The brand drug is covered on the pharmacy benefit for 44% of covered lives, and is found on the preferred tier for 10% of those lives. Remodulin’s global revenue was $599 million in 2018. 

MMIT Analytics, as of 3/28/19